Samrat Pharmachem Limited

As of June 30, 2026, Samrat Pharmachem Limited carries a market capitalization of 678.65M, placing it among publicly traded companies globally. Its enterprise value stands at 678.65M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Samrat Pharmachem Limited has 3.09M shares outstanding.

These figures are as of June 30, 2026.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 678.65M versus a market cap of 678.65M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 101.32M in revenue per employee across its workforce of 29.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Samrat Pharmachem Limited recorded 6.04M in income tax expense. The company reported a pretax loss of -16.03M and -22.07M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Samrat Pharmachem Limited's stock has declined approximately 4.85% over the past 52 weeks. The 50-day moving average sits at 237.50, while the 200-day moving average is 224.98.

Over the twelve months ended June 30, 2026, Samrat Pharmachem Limited generated 2.94B in revenue and converted that into -22.07M in net income, yielding earnings per share of -7.15. EBITDA reached -13.65M, while operating income came in at -21.03M.

Over the twelve months ended June 30, 2026, Samrat Pharmachem Limited posted a gross margin of 2.50, reflecting its pricing power and cost economics. The operating margin of -0.72 and net profit margin of -0.75 provide insight into operational efficiency.